Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions. The new method, known as SWIFT-seq, ...

Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of ...

Giving patients a whole-body MRI scan can detect minuscule amounts of myeloma, also known as minimal residue disease, even ...

AbbVie has acquired rights to a multispecific antibody that IGI Therapeutics designed to bind to three targets to treat multiple myeloma. Early Phase 1 results showed encouraging responses in a ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) for adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Bispecific antibodies are already available for treating multiple myeloma. FDA approval of Regeneron Pharmaceuticals’ new drug, Lynozyfic, comes with dosing flexibility that sets it apart from ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed bispecific antibody Lynozyfic has won an FDA approval with a more ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the approval is for patients with relapsed or refractory multiple myeloma who ...

Linvoseltamab represents a promising new approach to treating multiple myeloma through immune-based therapy. The FDA has granted accelerated approval to linvoseltamab (Lynozyfic, formerly REGN5458) ...

The EMA has extended the indications for Darzalex (daratumumab) to the treatment of adults at high risk of developing multiple myeloma.